Friday, June 10, 2022 NIAID Mouse Study Shows Benefits of COVID-19 Nasal Vaccine vs. Intramuscular This colorized scanning electron micrograph shows a cell (teal and green) infected with SARS-CoV-2 virus particles (purple and pink) isolated from a patient sample. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice. The vaccine tested uses an old immune-activation concept: modified vaccinia virus Ankara (MVA), which is a licensed smallpox and monkeypox vaccine and is being actively pursued as a vector for other infectious diseases. Advantages of the nasal MVA-based vaccine include targeting the virus at the most optimal location, generating more effective immune responses than a muscular vaccine, and those responses rapidly either prevent or accelerate virus elimination. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107